Cargando…
Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial
BACKGROUND: Adjuvant treatment for stage II colon cancer (CC) can be proposed to patients with high-risk disease. Recently, 2.35 ng/mL carcinoembryonic antigen (CEA) was identified as the best cut-off value. This post hoc analysis of the MOSAIC trial assessed post-operative CEA prognostic value for...
Autores principales: | Auclin, Edouard, André, Thierry, Taieb, Julien, Banzi, Maria, Van Laethem, Jean-Luc, Tabernero, Josep, Hickish, Tamas, de Gramont, Aimery, Vernerey, Dewi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738041/ https://www.ncbi.nlm.nih.gov/pubmed/31296923 http://dx.doi.org/10.1038/s41416-019-0521-7 |
Ejemplares similares
-
Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial
por: Chibaudel, Benoist, et al.
Publicado: (2020) -
Hepatic Arterial Infusion Chemotherapy With Folfirinox or Oxaliplatin Alone in Metastatic Colorectal Cancer
por: Randrian, Violaine, et al.
Publicado: (2022) -
ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy
por: Zaanan, Aziz, et al.
Publicado: (2014) -
CEA clearance pattern as a predictor of tumor response to neoadjuvant treatment in rectal cancer: a post-hoc analysis of FOWARC trial
por: Hu, Huabin, et al.
Publicado: (2018) -
Plasma CEA in the post-surgical monitoring of colorectal carcinoma.
por: Tate, H.
Publicado: (1982)